European regulators ordered a recall of all batches of Amgen’s Tavneos (avacopan) after the European Commission canceled its marketing authorization for the vasculitis treatment earlier this month. The action removes access while companies assess how to address regulatory and manufacturing requirements. The recall highlights how conditional decisions and authorization cancellations can quickly translate into operational disruptions across supply chains. It also reflects the scrutiny faced by newly approved or tightly managed therapies in Europe’s centralized system. For stakeholders, it may affect switching patterns among treating clinicians and payers, as well as near-term commercial forecasting for the therapy’s manufacturer and competitors.